DEVELOPMENT OF NOVEL IMAGING TECHNOLOGIES: (SBIR/STTR) INITIATIVE

Release date:  April 27, 2000

PA NUMBER: PAR-00-090

National Cancer Institute
National Center for Research Resources

Letter of Intent Receipt Dates: June 14, 2000 and February 9, 2001
Application Receipt Dates: July 19, 2000 and March 16, 2001

PURPOSE

The National Cancer Institute (NCI) invites applications on the development 
of novel image acquisition or enhancement methods, incorporating limited 
pilot or feasibility evaluations using either pre-clinical models or clinical 
studies.  This initiative is intended to facilitate the development of novel 
imaging technologies for early detection, screening, diagnosis and image 
guided treatment of cancer and other diseases.  The intent is to stimulate: 
(a) the development of highly innovative image acquisition and enhancement 
methods, including high risk/high gain research on technologies that exploit 
our knowledge of the molecular basis of cancer or other disease, and (b) the 
integration of these emerging technologies with traditional imaging methods 
for more effective solutions for health care delivery. 

The motivation for this Program Announcement (PA) is that current 
technologies for the molecular analysis of disease are largely restricted to 
in-vitro methods and need to be extended to the in-vivo situation. 
Furthermore, the use of molecular probes or tracers for imaging molecular 
events in pre-clinical or human investigations is considered essential for 
detection of molecular changes in-vivo. The development of innovative high-
resolution imaging methods at the cellular or molecular scales is needed, 
with a particular emphasis on identification and characterization of either 
the early formation of disease processes or early molecular changes during 
intervention or therapy.  

This program will utilize the Small Business Innovation Research (SBIR) and 
Small Business Technology Transfer (STTR) mechanisms, but will be run in 
parallel with a program of identical scientific scope that will utilize the 
newly created Phased Innovation Award mechanism PA PAR-00-089 (see 
http://grants.nih.gov/grants/guide/pa-files/PAR-00-089.html).  The SBIR and 
STTR applications received in response to this program announcement will 
undergo expedited review, have the opportunity for expedited transition of 
successful technology research into an expanded development phase, and will 
be subject to cost and duration limits comparable to the parallel Phased 
Innovation Award applications.  This program announcement must be read in 
conjunction with the OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF 
HEALTH, SMALL BUSINESS INNOVATION RESEARCH (SBIR) AND SMALL BUSINESS 
TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS (PHS 2000-2) 
http://grants.nih.gov/grants/funding/sbirsttr1/index.pdf.  SBIR Phase II 
Grant Application (PHS Form 6246-2) are available at 
http://grants.nih.gov/grants/funding/sbir2/index.htm.  The Phase II STTR 
instructions and application may be found on the Internet 
at: http://grants.nih.gov/grants/funding/sttr2/index.html
All of the instructions within the OMNIBUS SOLICITATIONS apply with the 
following exceptions:

o  Special receipt dates
o  Additional review considerations
o  Opportunity for 2 years of Phase I support

HEALTHY PEOPLE 2010

The Public Health Service (PHS) is committed to achieving the health 
promotion and disease prevention objectives of "Healthy People 2010," a PHS 
led national activity for setting priority areas. This PA, Development of 
Novel Imaging Technologies (SBIR/STTR) Initiative, is related to the priority 
area of cancer and several other priority areas. Potential applicants may 
obtain a copy of "Healthy People 2010" at 
http://www.health.gov/healthypeople/.

ELIGIBILITY REQUIREMENTS

Eligibility requirements for SBIR and STTR are described in the NIH Omnibus 
Solicitation for SBIR/STTR grant applications.  As stated in the REVIEW 
CONSIDERATIONS section, applications submitted in response to this PA will be 
reviewed by one or more NCI Special Emphasis Panels convened especially for 
this solicitation.

MECHANISM OF SUPPORT

Responsibility for the planning, direction and execution of the proposed 
project will be solely that of the applicant.  Awards will be administered 
under NIH grants policy stated in the NIH Grants Policy Statement, NIH 
publication 99-8 October 1998.

A.  FAST-TRACK APPLICATIONS.  Applications may be submitted for the 
FAST-TRACK review option.  Information on the FAST-TRACK process may be found 
at: http://grants.nih.gov/grants/funding/sbir.htm.  Applications will be 
accepted only on the receipt dates listed on the first page of this document.

To be eligible for the FAST-TRACK option, the Phase I (R41/43) application 
must include well defined quantifiable milestones that will be used to judge 
the success of the proposed research, as well as a credible plan to apply the 
selected technology in a pilot study of biological interest to cancer 
research for the Phase II R42/44 application. The FAST-TRACK must have a 
section labeled Milestones at the end of the Research Plan Phase I R41/43. 
This section must include well-defined quantifiable milestones for completion 
of Phase I R41/43, a discussion of the suitability of the proposed milestones 
for assessing the success in Phase I R41/43, and a discussion of the 
implications of successful completion of these milestones on the proposed 
Phase II R42/R44.

Applications submitted through the FAST-TRACK option are subject to the same 
total cost limits per year as when submitted outside of the FAST-TRACK 
option: Phase I R41/43, not to exceed $100,000 per year total direct costs 
excluding subcontractor indirect costs; Phase II normally not to exceed 
$500,000 total costs per year for R42 and $750,000 total costs per year for 
R44.  However, the total duration (Phase I plus Phase II applications) cannot 
exceed four years.  In any case, the Phase I application cannot exceed two 
years duration.

B.  INDIVIDUAL PHASE I APPLICATIONS. Phase I applications in response to this 
PA will be funded as Phase I SBIR Grants R43 or STTR Grants R41 with 
modifications as described below. Applications for Phase I grants should be 
prepared following the directions for Phase I SBIR/STTR applications as 
described in the NIH Omnibus Solicitation.  The NIH Omnibus SBIR/STTR 
Solicitation is available on the Internet at 
http://grants.nih.gov/grants/funding/sbirsttr1/index.htm

A limited number of hard copies of the NIH Omnibus SBIR and STTR Solicitation 
are available from:

PHS SBIR/STTR Solicitation Office
13685 Baltimore Avenue
Laurel, MD  20707-5096
Telephone:  (301) 206-9385
FAX:  (301) 206-9722
Email:  [email protected]

Project Period and Amount of Award.  Because the length of time and cost of 
research involving advanced technology projects often exceeds that normally 
awarded for SBIR/STTR grants, NCI and NCRR will entertain well-justified 
Phase I applications with a project period up to two years and a budget not 
to exceed $100,000 per year direct cost (maximum of $200,000 direct costs for 
to 2 years excluding subcontractor indirect costs).

Page Limitations.  The requirements for normal Phase I applications apply 
(see NIH OMNIBUS Solicitation).

C.  INDIVIDUAL PHASE II APPLICATIONS

Phase II applications in response to this PA will be awarded as Phase II SBIR 
Grants R44 or STTR Grants R42 with modifications as described below.  Phase 
II applications in response to this PA will only be accepted as competing 
continuations of previously funded NIH Phase I SBIR/STTR awards.  The Phase 
II application must be a logical extension of the Phase I research.

Applications for Phase II awards should be prepared following the 
instructions for NIH Phase II SBIR/STTR applications.  The Phase II SBIR 
instructions and application may be found on the Internet at: 
http://grants.nih.gov/grants/funding/phs398/phs398.html.

The Phase II STTR instructions and application may be found on the Internet 
at:
http://grants.nih.gov/grants/funding/sttr2/index.html

Project Period and Amount of Award.  Because the length of time and cost of 
research often exceeds that normally awarded for SBIR grants, NCI and NCRR 
will entertain well-justified Phase II applications for this SBIR/STTR award 
with a project period up to three years with budget levels appropriate for 
the work proposed.

Potential applicants who believe that they may be eligible for the SBIR/STTR 
award should consult the PHS SBIR and STTR Omnibus Solicitation prior to 
discussions of their eligibility with NCI and NCRR staff listed under 
INQUIRIES.

BACKGROUND

Significant advances in medical imaging technologies have been made over the 
last 25 years in such areas as magnetic resonance imaging (MRI), computed 
tomography (CT), nuclear medicine and ultrasound. However, these advances 
largely focused on structural or anatomic imaging at the organ or tissue 
level. There is clearly a need and opportunity now to stimulate the 
development and integration of novel imaging technologies that exploit our 
current knowledge of the genetic and molecular bases of cancer and other 
diseases and conditions.  Those molecular biological discoveries have great 
implications for prevention, detection and targeted therapy of cancer and 
other diseases. Imaging technologies that can provide in vivo the same kind 
of cellular and molecular information that is currently available only from 
in vitro techniques would be very useful. This is commonly referred to as in 
vivo molecular imaging. 

Participants at several NCI-supported forums over the last few years [Imaging 
Sciences Working Group (ISWG) July 1997; Lung Imaging Workshop: Technology 
Transfer, Jan 1997; Computer Aided Diagnosis and 3D Image Analysis, Oct 1998; 
Quantitative In-Vivo Functional Imaging in Oncology, Jan 1999; Focus Group on 
Magnetic Resonance Spectroscopy (MRS) in Clinical Oncology, April 1999; and 
NIH BECON Symposium, June 1999] stressed the need for NCI to support 
bioengineering and technology development by academia and industry.  The 
needs are to (a) promote the development of very novel (high risk, high gain) 
technologies, including continued support for their maturation and full 
exploitation, (b) promote system integration of technologies for targeted 
applications, and (c) improve technology transfer by promoting partnerships 
between academia and industry.  

Development of novel imaging technologies will require a multidisciplinary 
team approach with broad expertise in a variety of research areas.  Such 
varied expertise, potentially including but not limited to, expertise in 
imaging physics, molecular and cellular biology, informatics and 
biostatistics exists in ongoing cancer centers and clinical trials 
cooperative groups. The coordination and collaboration of investigators from 
these various disciplines to demonstrate the utility and applicability of new 
imaging methods is considered to be a high priority.

RESEARCH OBJECTIVES

The intent of this PA is to stimulate: (a) the development of highly 
innovative image acquisition and enhancement methods, including high risk/ 
high gain projects that exploit our expanding knowledge of the molecular 
basis of cancer and other diseases, and (b) the integration of these emerging 
technologies with traditional imaging modalities for more effective solutions 
for cancer and other diseases. In particular, the development of innovative 
high-resolution imaging methods at the cellular or molecular scales is 
needed, with emphasis on identification and characterization of either the 
early formation of disease or early molecular changes during intervention or 
therapy. For many technologies that have potential for molecular imaging, the 
use of probes or tracers is considered essential for detection of molecular 
changes in-vivo. 

The following clinical applications are appropriate for inclusion in proposed 
projects:

*Imaging to detect early changes. 
The development of innovative high-resolution imaging methods at the cellular 
or molecular scales is encouraged, with a particular intent to identify and 
characterize pre-malignant abnormalities or other early changes. Novel 
solutions for in-vivo microscopic imaging sensors, or microscopic implanted 
devices with high spatial, contrast and temporal resolution are encouraged. 
Similarly the use of contrast enhancement methods and imaging probes is also 
encouraged. The imaging methodologies proposed should emphasize analysis of 
molecular events on the path to disease. 

*Large scale screening applications for cancer and other diseases. 
Development and optimization of efficient low-cost imaging systems for rapid 
and automated large-scale screening with the intent of achieving 
significantly higher sensitivity and specificity for cancer and other disease 
detection are encouraged.  Applications could address significant innovative 
improvements to current imaging methods or new emerging imaging sensors.  
Research topics of interest include, but are not limited to, technologies for 
molecular imaging, means to significantly reduce imaging time or motion 
effects, use of novel contrast agents or imaging probes, and use of 
technologies that do not involve ionization radiation.  System integration 
could include a variety of image processing techniques including temporal 
analysis of serial studies, close to real-time image processing, novel image 
display methods, and related imaging informatics and information reduction 
methods for more cost-effective solutions for screening. 

*Imaging for diagnosis, staging, or monitoring the effects of therapy. 
This initiative encourages the development of novel imaging methods such as 
functional or molecular imaging or spectroscopy methods that would 
significantly improve the specificity of diagnosis of cancer and other 
diseases, allow deterministic methods or patient-specific staging, or measure 
early effects of therapy.  Examples of system integration would include image 
fusion or registration from the different modalities employed, development of 
software methods that would estimate the probability of malignancy or other 
specific disease identification, quantitative information for monitoring the 
effects of therapy, and close to real-time image analysis.

*Image guided biopsy (IGB) and therapy (IGT).  
Novel approaches using imaging technologies are needed to significantly 
improve specificity, to identify lesion extent and microscopic involvement, 
and to minimize the tissue damage accompanying biopsy and therapy. Of 
particular interest are innovative approaches to IGB or IGT that include 
novel imaging sensors that provide information at the cellular or molecular 
level. Examples of system integration that are of interest include, but are 
not limited to, navigational systems, registration methods for several 
imaging modalities, real-time feedback mechanisms for controlling therapy or 
the use of methods that are adaptive or allow patient-specific optimization 
of treatment.

Partnerships of appropriate medical institutions with medical device 
manufacturers to facilitate the integration of system components are 
encouraged.  

INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS

It is the policy of the NIH that women and members of minority groups and 
their subpopulations must be included in all NIH supported biomedical and 
behavioral research projects involving human subjects, unless a clear and 
compelling rationale and justification is provided that inclusion is 
inappropriate with respect to the health of the subjects or the purpose of 
the research.  This policy results from the NIH Revitalization Act of 1993
(Section 492B of Public Law 103-43).

All investigators proposing research involving human subjects should read the 
NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical 
Research", which have been published in the Federal Register of March 28, 
1994(FR 59 14508-14513) and in the NIH Guide for Grants and Contracts, Volume 
23, Number 11, March 18, 1994, available on the web at the following URL 
address:  http://grants.nih.gov/grants/guide/notice-files/not94-100.html

INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS

It is the policy of NIH that children (i.e., individuals under the age of 21) 
must be included in all human subjects research, conducted or supported by 
the NIH, unless there are clear and compelling scientific and ethical reasons 
not to include them.  This policy applies to all initial (Type 1) 
applications submitted for receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should read the 
"NIH Policy and Guidelines on the Inclusion of Children as Participants in 
Research Involving Human Subjects" that was published in the "NIH Guide for 
Grants and Contracts", March 6, 1998, and is available at the following URL 
address: http://grants.nih.gov/grants/guide/notice-files/not98-024.html

Investigators also may obtain copies of the policy from the program staff 
listed under INQUIRIES.  Program staff may also provide additional relevant 
information concerning the policy.

LETTER OF INTENT

Prospective applicants are asked to submit, by the date listed at the 
beginning of this PA, a letter of intent that includes a descriptive title of 
the proposed research, the name, address, telephone number, and e-mail 
address of the Principal Investigator, the identities of other key personnel 
and participating institutions, and the number and title of the PA in 
response to which the application may be submitted.

Although a letter of intent is not required, is not binding, and does not 
enter into the review of a subsequent application, the information that it 
contains allows NCI staff to estimate the potential review workload and plan 
the review.  The letter of intent is to be sent to Dr. Barbara Croft at the 
address listed under INQUIRIES.

APPLICATION PROCEDURES

The OMNIBUS SOLICITATION for the SBIR and STTR programs is available 
electronically through the NIH, Office of Extramural Research Small Business 
Funding Opportunities web site at 
http://grants.nih.gov/grants/funding/sbir.htm. Hard copies, subject to 
availability, may be obtained from the PHS SBIR/STTR Solicitation Office, 
phone (301) 206-9385; FAX (301) 206-9722; email [email protected].  Helpful 
information for preparation of the application can be obtained: 
http://grants.nih.gov/grants/funding/sbir.htm

Applications are to be submitted on the grant application form PHS 6246-1 
(1/98) (SBIR) and PHS 6246-3 (STTR) (1/98) located in the back pages of the 
OMNIBUS SOLICITATIONS, and will be accepted at the application deadlines as 
indicated on the first page of this document.

THE TITLE AND NUMBER OF THIS PA MUST BE TYPED IN LINE 2 ON THE FACE PAGE OF 
THE APPLICATION.

The OMNIBUS SOLICITATIONS give the normal levels of support and period of 
time for SBIR and STTR Phase I and II awards.  However, these award levels 
are guidelines and not ceilings.  Therefore, larger budgets with longer 
periods of time may be requested if required to complete the proposed 
research.  As stated under MECHANISM OF SUPPORT section, Phase I applications 
submitted in response to this PA can have a project period of up to two years 
and a budget not to exceed $100,000 per year direct cost excluding 
subcontractor indirect costs.

The second year of the Phase I budget should be included on the Budget 
Justification page, using categorical totals if costs deviate significantly 
from the first year of the budget, with narrative justifications for the 
increase(s).  If the second year simply escalates due to cost of living 
factors, a statement to that effect with the escalation factor should be 
included rather than categorical totals. Phase II applications submitted in 
response to this PA have no budget limitations.  The total duration (Phase I 
and Phase II application) cannot exceed four years.

In order to apply for the FAST-TRACK option, applications for both Phase I 
and Phase II must be submitted together according to the instructions for 
FAST TRACK applications as described in the OMNIBUS SOLICITATIONS.  The Phase 
I application must specify clear, well-defined quantifiable milestones that 
should be achieved prior to Phase II funding.  Milestones should be located 
in a separate section at the end of the Research Plan of the Phase I and 
should be indicated in the Table of Contents.  Failure to provide measurable 
milestones and sufficient detail may be sufficient reason for the peer review 
committee to exclude the Phase II application from FAST-TRACK review. If so, 
at a later date, the applicant may apply for Phase II support through normal 
application procedures.  Such applications will be reviewed by the Center for 
Scientific Review or by a special review group convened in response to a 
re-issuance of this PAR, if applicable.

An additional requirement of the FAST-TRACK mechanism is the Product 
Development Plan.  The small business must submit a concise Product 
Development Plan (limited to five pages) as an Appendix to the Phase II 
application addressing the four areas described in the instructions for 
FAST-TRACK applications in the OMNIBUS SOLICITATIONS.  In the event that an 
applicant feels that technology is too proprietary to disclose, applicants at 
a minimum should provide a demonstration (e.g., results) of the capabilities 
of the proposed technology.

All applications and proposals for NIH funding must be self-contained within 
specified page limitations.  Unless otherwise specified in an NIH 
solicitation, internet addresses (URLs) should not be used to provide 
information necessary to the review because reviewers are under no obligation 
to view the Internet sites.  Reviewers are cautioned that their anonymity may 
be compromised when they directly access an Internet site.  (see  
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-004.html).

The completed original application and one legible copy must be sent or 
delivered to:

CENTER FOR SCIENTIFIC REVIEW
NATIONAL INSTITUTES OF HEALTH
6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710
BETHESDA, MD  20892-7710
BETHESDA, MD  20817 (for express/courier service)

To expedite the review process, at the time of submission, send one 
additional
copy of the application to:

Ms. Toby Friedberg
Referral Officer
National Cancer Institute
6116 Executive Boulevard, Room 8062, MSC 8239
Bethesda, MD 20892-8239
Rockville, MD 20852 (for overnight/courier service)
Telephone:    (301) 496-3428
FAX:    (301) 402-0275

Applications must be received by the receipt dates listed at the beginning of 
this PA

REVIEW CONSIDERATIONS

Upon receipt, applications will be reviewed by the CSR for completeness and 
by NCI program staff for adherence to the guidelines of this PA.  
Applications not adhering to application instructions described above and 
those applications that are incomplete as determined by CSR or by NCI program 
staff will be returned to the applicant without review.

Applications that are complete and adhere to the guidelines of this PA will 
be evaluated for scientific and technical merit by an appropriate peer review 
group convened by the NCI in accordance with the review criteria stated 
below.  As part of the initial merit review, all applicants will receive a 
written critique and may undergo a process in which only those applications 
deemed to have the highest scientific merit, generally the top half of the 
applications, will be discussed, assigned a priority score, and receive a 
second level review by the National Cancer Advisory Board (NCAB) and/or the 
National Advisory Research Resources Council (NARRC).

Review Criteria: 

Review criteria are described in the NIH Omnibus Solicitation and available 
on the web at the following URL address: 
http://grants.nih.gov/grants/funding/sbirsttr1/index.htm

The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  The 
reviewers will comment on the following aspects of the application in their 
written critiques in order to judge the likelihood that the proposed research 
will have a substantial impact on the pursuit of these goals.  Each of these 
criteria will be addressed and considered by the reviewers in assigning the 
overall score, weighting them as appropriate for each application.  Note that 
the application does not need to be strong in all categories to be judged 
likely to have a major scientific impact and thus deserve a high priority 
score. 


1.  Significance.  Does this study address an important problem? If the aims 
of the application are achieved, how will scientific knowledge be advanced?  
What will be the effect of these studies on the concepts or methods that 
drive this field?  To what degree does the technology support the needs for 
the targeted disease?

2.  Approach.  Are the conceptual framework, design, and methods adequately 
developed, well integrated, and appropriate to the aims of the project?  Does 
the applicant acknowledge potential problem areas and consider alternative 
tactics? What is the time frame for developing the proposed technologies and 
suitability of this time frame for meeting the community's needs?  How easy 
will it be to use the proposed technology?  Are the plans for the proposed 
technology, its integration as an effective solution for implementation and 
dissemination adequate? If partnerships are proposed, how will they 
facilitate the development and integration of system components? 

3.    Milestones.  How appropriate are the proposed milestones against which 
to evaluate
the demonstration of feasibility for transition to the Phase II application?

4.     Innovation.  Does the project employ novel concepts, approaches or 
methods? Are the aims original and innovative? Does the project challenge 
existing paradigms or develop new methodologies or technologies? What is the 
throughput and cost effectiveness of the proposed technology?  What 
additional uses can be projected for the proposed technology?

5.     Investigator.  Is the investigator appropriately trained and well 
suited to carry out this work?  Is the work proposed appropriate to the 
experience level of the principal investigator and other researchers (if 
any)?

6.     Environment.  Does the scientific environment in which the work will 
be done contribute to the probability of success?  Do the proposed 
experiments take advantage of unique features of the scientific environment 
or employ useful collaborative arrangements? Is there evidence of 
institutional support?

Additional Considerations

In addition to the above criteria, in accordance with NIH policy, all 
applications will also be reviewed with respect to the following:

o The adequacy of plans to include both genders, minorities and their 
subgroups, and children as appropriate for the scientific goals of the 
research. Plans for the recruitment and retention of subjects will also be 
evaluated.

o The reasonableness of the proposed budget and duration in relation to the 
proposed research.

o The adequacy of the proposed protection for humans, animals or the 
environment, to the extent they may be adversely affected by the project(s) 
proposed in the application.

AWARD CRITERIA

Applications will compete for available funds with all other recommended SBIR 
and STTR applications.  Funding decisions for Phase I will be based on 
quality of the proposed project as determined by peer review, availability of 
funds, and program priority.

Fast-Track Phase II applications may be funded following submission of the 
Phase I progress report and other documents necessary for continuation.  
Phase II applications will be selected for funding based on the initial 
priority score, NCI and NCRR 's assessment of the Phase I progress and 
determination that Phase I milestones were achieved, programmatic relevance 
the project potential for commercial success, and the availability of funds.

INQUIRIES

Inquiries are encouraged.  The opportunity to clarify any issues or questions 
from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Barbara Y. Croft, Ph.D.
Biomedical Imaging Program
National Cancer Institute
6130 Executive Plaza, Suite 800
Bethesda, MD  20892-2590
Rockville, MD 20852 (for express/courier service)
Telephone:  (301) 496-9531
FAX:  (301) 480-5785
Email: [email protected]

Abraham Levy, Ph.D.
Biomedical Technology
National Center for Research Resources
6705 Rockledge Drive, Room 6150
Bethesda, MD  20892-7965
Telephone:  (301) 435-0755
FAX:  (301)480-3659
Email: [email protected]

Direct inquiries regarding fiscal matters to:

Ms. Kathleen Shino
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Suite 243
6120 Executive Boulevard
Bethesda, MD  20892-7150
Telephone:  (301) 496-8635
FAX:  (301) 496-8601
Email: [email protected]

Ms. Irene Haas Grissom
Grants Management Analyst
Office of Grants Management
National Center for Research Resources, NIH
6705 Rockledge Drive, Room 2086
Bethesda, Maryland  20892-7965
Phone: 301-435-0848
Fax: 301-480-3777
Email:  [email protected]

Direct inquiries regarding review matters to:

Ms. Toby Friedberg
Division of Extramural Activities
National Cancer Institute
6116 Executive Boulevard, Room 8062
Bethesda, MD  20892-7399
Rockville, MD 20852 (for express/courier service)
Telephone:  (301) 496-3428
FAX:  (301) 402-0275
Email: [email protected]

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance 
No.93.394, Cancer Detection and Diagnosis Research (NCI) and No.93.371, 
Biomedical Technology (NCRR).  Awards are made under authorization of 
Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 
and 284) and administered under NIH grants policies and Federal Regulations 
42 CFR 52 and 45 CFR Parts 74 and 92.  This program is not subject to the 
intergovernmental review requirements of Executive Order 12372 or Health 
Systems Agency review.

The PHS strongly encourages all grant and contract recipients to provide a 
smoke-free workplace and promote the non-use of all tobacco products.  In 
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking 
in certain facilities (or in some cases, any portion of a facility) in which 
regular or routine education, library, day care, health care or early 
childhood development services are provided to children.  This is consistent 
with the PHS mission to protect and advance the physical and mental health of 
the American people. 

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

			Department of Health and Human Services (HHS)
NIH... Turning Discovery Into Health®